WASHINGTON--(BUSINESS WIRE)--OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS), today announced the appointment of Robert Petit, Ph.D., as its Chief Medical and Scientific Advisor. He is continuing to support the technology that he helped to develop at Advaxis.

"I am excited to join the OS Therapies team and contribute toward realizing the potential of the OS Therapies lead program in the treatment of osteosarcoma,” said Dr. Petit. “I also look forward to furthering the mission of OS Therapies by assisting in building a pipeline of assets that will improve treatment options and outcomes for patients with osteosarcoma.”

https://www.businesswire.com/news/home/20190918005918/en/Dr.-Robert-Petit-Passion-OS-Therapies-Chief

Dr. Robert Petit Follows His Passion to OS Therapies as Chief Medical & Scientific Advisor

September 18, 2019

 

OS Therapies to locate at INOVA Center for Personalized Health

May 15, 2018

OS Therapies is excited to have located headquarters within the new INOVA Center for Personalized Health (ICPH), and specifically the Inova Strategic Investments (ISI) and the Inova Personalized Health Accelerator (IPHA). 

Inova is a global leader in personalized health, which leverages precision medicine to predict, prevent and treat disease, enabling individuals to live longer, healthier lives. Inova Strategic Investments is the strategic investing division of the Inova Health System. ISI targets early to mid-stage companies that are interested in partnering to deploy solutions across the Inova Health System, working collaboratively as a key customer and strategic investor. IPHA is the Inova Health System’s accelerator program for the next generation of companies that deliver on the promise of personalized health.


JAMA Article - New Business Models to Accelerate Peds Onc Therapeutics

June 2, 2018

Few patient populations are as helpless and in need of advocacy as children with cancer. Pharmaceutical companies have historically faced significant financial disincentives to pursue pediatric oncology therapeutics, including low incidence, high costs of conducting pediatric trials, and a lack of funding for early-stage research.

Phase diversification increases the likelihood of a successful drug and yielded expected returns of −5.3% to 50.1%. Standard philanthropic grants had a marginal association with expected returns, and government guarantees had a greater association by reducing downside exposure. An assessment of a proposed venture philanthropy fund demonstrated stronger performance than the purely private-sector–funded portfolio or those with traditional amounts of philanthropic support.

https://jamanetwork.com/journals/jamaoncology/article-abstract/2683253


Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma

September 4, 2018

 

PRINCETON, N.J. and FAIRFAX, Va.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, and OS Therapies LLC, a clinical-stage therapeutic company focused on the identification, development and commercialization of treatments for osteosarcoma, today announced that Advaxis has granted a license to OS Therapies for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans.

 

https://www.businesswire.com/news/home/20180904005224/en/Advaxis-Licenses-ADXS-HER2-OS-Therapies-Evaluation-Treatment